HER2+ mBC after 2+ anti-HER2 regimens.
15 mg/kg IV Q3W.
250 mg/10 mL vial
None listed.
Fatigue (32%), Nausea (29%), Diarrhea (25%), Infusion Reactions (13%), Cough (14%), Headache (12%)
Consult the complete prescribing information for a comprehensive list of adverse reactions and their frequencies.
No CYP interactions.
Consult the full prescribing information for pregnancy-related considerations.
Refer to prescribing information for lactation guidance.
Pediatric safety and efficacy information is detailed in the full label.
Dose modifications for organ impairment are specified in the complete prescribing information.
Fc-engineered anti-HER2 mAb with enhanced ADCC.
t1/2: ~19 days.
Clinical efficacy and safety data supporting the approval are available in the full prescribing information and from the clinical trials listed below.
Margenza has FDA-approved indications across the following cancer types covered on CancerDrugEvidence:
Margenza (margetuximab-cmkb) is an FDA-approved oncology agent. Refer to the full prescribing information for complete indication details.
Refer to the full prescribing information for dosing schedules, administration instructions, and dose modifications.
Fc-engineered anti-HER2 mAb with enhanced ADCC.
Fatigue (32%), Nausea (29%), Diarrhea (25%), Infusion Reactions (13%), Cough (14%), Headache (12%) Fatigue 32% Nausea 29% Diarrhea 25% Infusion Reactions 13% Cough 14% Headache 12%